FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Flagship Ventures Fund IV, L.P.
  2. Issuer Name and Ticker or Trading Symbol
Syros Pharmaceuticals, Inc. [SYRS]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
55 CAMBRIDGE PARKWAY, SUITE 800E
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2017
(Street)

CAMBRIDGE, MA 02142
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/17/2017   J(1)   1,295,997 D (1) 2,378,663 D (2)  
Common Stock 08/17/2017   J(1)   306,222 D (1) 612,442 I See Footnote (3)
Common Stock 08/17/2017   J(1)   54,293 D (1) 0 (1) I See Footnote (4)
Common Stock               213,332 I See Footnote (5)
Common Stock               24,527 (1) I See Footnote (6)
Common Stock               24,527 (1) I See Footnote (7)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Flagship Ventures Fund IV, L.P.
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142
    X    
Flagship Ventures Fund IV-Rx, L.P.
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142
    X    
Flagship VentureLabs IV, LLC
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142
    X    
Flagship Ventures Fund IV General Partner LLC
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142
    X    
AFEYAN NOUBAR
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142
    X    
KANIA EDWIN M JR
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142
    X    

Signatures

 FLAGSHIP VENTURES FUND IV, L.P., By: Flagship Ventures Fund IV General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Manager   08/21/2017
**Signature of Reporting Person Date

 FLAGSHIP VENTURES FUND IV-RX, L.P., By: Flagship Ventures Fund IV General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Manager   08/21/2017
**Signature of Reporting Person Date

 FLAGSHIP VENTURELABS IV, LLC, By: Flagship Ventures Fund IV, L.P., By: Flagship Ventures Fund IV General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Manager   08/21/2017
**Signature of Reporting Person Date

 FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Manager   08/21/2017
**Signature of Reporting Person Date

 /s/ Noubar B. Afeyan, Ph.D.   08/21/2017
**Signature of Reporting Person Date

 /s/ Edwin M. Kania, Jr.   08/21/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,295,997 shares and 306,222 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 54,283 shares and 10 shares it received from Flagship IV and Flagship IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship IV LLC, each received 24,527 shares through Flagship IV LLC's distribution.
(2) Held by Flagship IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons other than Flagship IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
(3) Held by Flagship IV-Rx. Flagship IV LLC is the general partner of Flagship IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons other than Flagship IV-Rx disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
(4) Held by Flagship IV LLC. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV LLC. Each of the filing persons other than Flagship IV LLC disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
(5) Held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship IV is the manager of VentureLabs IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV, Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by VentureLabs IV. Each of the filing persons other than VentureLabs IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
(6) Held by Noubar B. Afeyan, Ph.D. Each of the filing persons other than Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
(7) Held by Edwin M. Kania, Jr. Each of the filing persons other than Edwin M. Kania, Jr. disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.